Vapor-Phase Hydrogen Peroxide Resistance of Environmental Isolates

Reich,Robert;

Vapor-Phase Hydrogen Peroxide Resistance of Environmental Isolates

August 2, 2004

By Robert R. Reich

Publication

Article

Pharmaceutical TechnologyPharmaceutical Technology-08-02-2004

Volume 28

Issue 8

The authors examine the VHP resistance of microbial isolates recovered from controlled environments and compared them with commercially available biological indicators under various test conditions.

External Link - article-112218.pdf

Articles in this issue

Stable Isotopic Characterization of Analgesic Drugs

August 2004

Increased Outsourcing Driving Investments in CRO Industry

E-Health Information Campaign Shapes Pharmaceutical Regulation

Photosensitivity of Internal Standard Valerophenone Used in USP Ibuprofen Bulk Drug and Tablet Assay and Its Effect on the Quantitation of Ibuprofen and Its Impurities

In the Spotlight-August 2004

Interphex Delivers Packaging Solutions

Vapor-Phase Hydrogen Peroxide Resistance of Environmental Isolates

Decoding the US Pharmacopeia

Related Content

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Circio and Certest to Collaborate on LNP Formulations

Feliza Mirasol

November 21st 2024

Article

The companies will collaborate to create and test circVec DNA–LNP formulations for use in potential therapeutic applications.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas

June 25th 2024

Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

CDMO SEKISUI Expands its CGMP Biopharma Manufacturing Capacity

Feliza Mirasol

November 20th 2024

Article

SEKISUI has used a £15.7 million (US$20.7 million) investment to expand its clinical-grade drug substance manufacturing at its UK site.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol

April 30th 2024

Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Frontier Scientific Solutions Plans a Global Free Trade Zone Gateway to Supply Life Sciences Industry on Back of $1.5 Billion Investment

Feliza Mirasol

November 16th 2024

Article

Frontier Scientific Solutions has unveiled plans to use a $1.5 billion commitment from a major investor to create a global free trade zone gateway to facilitate the life sciences supply chain using Wilmington International Airport in North Carolina.